@article{389ca6ea7e60412aab4c60a019110e50,
title = "An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis",
abstract = "Introduction: With the increasing use of immune checkpoint inhibitors (ICI) for cancer, there is a growing burden on the healthcare system to provide care for the toxicities associated with these agents. Herein, we aim to identify and describe the distribution of encounters seen in an urgent care setting for immune-related adverse events (irAEs) and the clinical outcomes from irAE management. Methods: Patient demographics, disease characteristics, and treatment data were collected retrospectively from encounters at an oncology Urgent Care Clinic (UCC) from a single tertiary center for upper aerodigestive malignancies from 1 July 2018 to 30 June 2019. Data were summarized using descriptive statistics with odds ratios for associations between patient features and hospitalization after UCC evaluation. Results: We identified 494 encounters from 289 individual patients over the study period. A history of ICI therapy was noted in 34% (n = 170/494) of encounters and 29 encounters (29/170, 17%) were confirmed and treated as irAEs. For those treated for irAEs, the majority (n = 19/29; 66%) were discharged home. Having an irAE was associated with an increased risk of hospitalization compared to non-irAEs (OR 5.66; 95% CI 2.15–14.89; p < 0.001). Conclusion: In this single institution experience, the majority of UCC encounters for confirmed irAEs were safely managed within the UCC. In ICI-treated patients, having an irAE was associated with an increased risk of hospitalization versus non-irAEs.",
keywords = "care delivery, immune-checkpoint inhibitors, immune-related adverse events, toxicity, urgent care",
author = "Liang, {Kai Li} and Sean Tackett and Samantha Myers and Brahmer, {Julie R.} and Browner, {Ilene S.} and Ettinger, {David S.} and Forde, {Patrick M.} and Hales, {Russell K.} and Hann, {Christine L.} and Lam, {Vincent K.} and Marrone, {Kristen A.} and Tricia Patel and Valerie Peterson and Sarah Sagorsky and Michelle Turner and Voong, {Khinh R.} and Jarushka Naidoo and Feliciano, {Josephine L.}",
note = "Funding Information: We thank the Johns Hopkins Center for Innovative Medicine for their support. Funding Information: Conflicts of Interest: The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. The following authors declare no conflict of interest: K.L., S.T., S.M., I.S.B., R.K.H., T.P., V.P. and N.T. Author{\textquoteright}s disclosures of potential conflicts of interests are as followed: J.R.B. reports consulting/advising for Amgen, AstraZeneca, BMS, Genentech/Roche, Eli Lilly, GlaxoSmithKline, Merck, Sanofi, Regeneron, receiving grant/research funding from: AstraZeneca, BMS, Genentech/Roche, Merck, RAPT Therapeutics, Inc., Revolution Medicines and is on a data and safety monitoring board/committee for: GlaxoSmithKline, Sanofi, Janssen. D.S.E. reports consulting/advising for: NCCN Guideline Panel Editorial Board Member to JNCCN, Consult to Harborside—Publisher of JNCCN, Editor-in-Chief, Current Treatment Options In Oncology, NCCN—Member, Board of Directors. P.M.F. reports consulting/advising for: Amgen, AZ, Iteos, BMS, Janssen, Daichii, receiving grant/research funding from: AstraZeneca, BMS, Corvus, Kyowa, Novartis, and in on a data and safety monitoring board/committee for: Flame, Polaris. C.L.H. reports consulting/advising for: AbbVie, Amgen, AstraZeneca, BMS, Genentech/Roche and GSK, receiving grant/research funding from: AbbVie, Amgen, AstraZeneca, BMS, and GSK. V.K.L. reports consulting/advising for: Company: Takeda, Seattle Genetics, Bristol-Myers Squibb, AstraZeneca, Guardant Health, receiving research funding: Guardant Health, Takeda, GlaxoSmithKline, BMS, Merck. K.A.M. reports consulting/advising for: AstraZeneca, Mirati, Puma. J.N. reports consulting/advising for: Merck, As-traZeneca, Bristol Myers Squibb, Roche/Genentech, Takeda, Pfizer, Daiichi Sankyo, receiving research funding from: Merck, AstraZeneca and has receiving Honoraria from: Merck, AstraZeneca, Bristol Myers Squibb, Roche/Genentech, Takeda, Pfizer, Daiichi Sankyo. S.S. reports consulting/advising: Syneos, AlphaRx, ZoomRx, SITC Panel for IO Toxicity and NSCLC. K.R. reports consulting/advising for: AstraZeneca. J.L.F. reports consulting/advising for: Merck, AstraZeneca, Eli Lilly, Bristol Myers Squibb, Genetech, Regeneron, Pfizer, Janssen and receiving research funding from: Bristol Myers Squibb, AstraZeneca, Pfizer. Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2022",
month = jun,
doi = "10.3390/curroncol29060347",
language = "English (US)",
volume = "29",
pages = "4342--4353",
journal = "Current Oncology",
issn = "1198-0052",
publisher = "Multimed Inc.",
number = "6",
}